These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33754202)

  • 1. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.
    Kinugasa E; Igawa K; Shimada H; Kondo M; Funakoshi S; Imada N; Itami N; Fukazawa N; Takubo R; Kawata Y; Murota H
    Clin Exp Nephrol; 2021 Aug; 25(8):875-884. PubMed ID: 33754202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.
    Yokozeki H; Murota H; Matsumura T; Komazaki H;
    Br J Dermatol; 2024 Jul; 191(2):200-208. PubMed ID: 38629497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
    Igarashi A; Katsunuma T; Matsumura T; Komazaki H;
    Br J Dermatol; 2023 Dec; 190(1):20-28. PubMed ID: 37522351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
    Ruzicka T; Hanifin JM; Furue M; Pulka G; Mlynarczyk I; Wollenberg A; Galus R; Etoh T; Mihara R; Yoshida H; Stewart J; Kabashima K;
    N Engl J Med; 2017 Mar; 376(9):826-835. PubMed ID: 28249150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
    N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.
    Kabashima K; Furue M; Hanifin JM; Pulka G; Wollenberg A; Galus R; Etoh T; Mihara R; Nakano M; Ruzicka T
    J Allergy Clin Immunol; 2018 Oct; 142(4):1121-1130.e7. PubMed ID: 29753033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
    Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
    J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
    Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
    N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.
    Wikström B; Gellert R; Ladefoged SD; Danda Y; Akai M; Ide K; Ogasawara M; Kawashima Y; Ueno K; Mori A; Ueno Y
    J Am Soc Nephrol; 2005 Dec; 16(12):3742-7. PubMed ID: 16251241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
    Kaneda N
    Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.
    Mathur VS; Kumar J; Crawford PW; Hait H; Sciascia T;
    Am J Nephrol; 2017; 46(6):450-458. PubMed ID: 29253847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial.
    Kabashima K; Matsumura T; Hayakawa Y; Kawashima M;
    J Dermatolog Treat; 2023 Dec; 34(1):2177096. PubMed ID: 36779675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    Br J Dermatol; 2022 Apr; 186(4):642-651. PubMed ID: 34726262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
    Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
    JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gabapentin and uremic pruritus in hemodialysis patients.
    Razeghi E; Eskandari D; Ganji MR; Meysamie AP; Togha M; Khashayar P
    Ren Fail; 2009; 31(2):85-90. PubMed ID: 19212903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
    Silverberg JI; Pinter A; Alavi A; Lynde C; Bouaziz JD; Wollenberg A; Murrell DF; Alpizar S; Laquer V; Chaouche K; Ahmad F; Armstrong JM; Piketty C
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1562-1568. PubMed ID: 33711179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
    Liang J; Hu F; Dan M; Sang Y; Abulikemu K; Wang Q; Hong Y; Kang X
    Front Immunol; 2022; 13():825312. PubMed ID: 35558086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of sertraline in alleviating uremic pruritus in hemodialysis patients: a randomized clinical trial.
    Elsayed MM; Elgohary IE; Abdelhamid HHS; Zaki SA
    BMC Nephrol; 2023 Jun; 24(1):155. PubMed ID: 37270517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.